Mag. Dr. Verena Battisti

Verena Battisti is a senior postdoctoral researcher and team lead at the University of Vienna's Cheminformatics Research Group. Specializing in drug discovery, her research includes hit identification, molecular design, synthesis, lead optimization, and essential in vitro and in vivo assays. Further, her research focuses on Computer Aided Drug Design (CADD) and AI-driven chemoinformatics, facilitating interdisciplinary scientific methods to develop small-molecule inhibitors with antiviral activity. 

In 2017, Verena obtained her Master of Science in Pharmaceutical Sciences from the University of Vienna, specializing in medicinal chemistry and drug development. During her master's program, she conducted research in anticancer pharmaceutical chemistry, focusing on designing and synthesizing Calothrixin analogues, and graduated with distinction.

Verena's primary research area focuses on the development of small-molecule inhibitors with antiviral activity, particularly with anti-Chikungunya activity. Within her PhD project, she performed a hit-to-lead and lead optimization, specializing in computational and medicinal chemistry. Further, she coordinated the biological and essential in vitro assays to thoroughly assess critical ADMET characteristics in early drug development. Verena completed her PhD program with distinction in November 2022. Subsequently, she assumed the role of Senior Post-Doc at the Chemoinformatic Research Group at the University of Vienna, where she is now focused on AI-driven chemoinformatics.

In addition to her research, Verena actively contributes to the scientific community by serving as a reviewer for esteemed publications and organizing and coordinating scientific communications. Furthermore, she is involved in teaching activities at the University of Vienna.

Researchgate: www.researchgate.net/profile/Verena-Battisti

ORCID: orcid.org/0000-0001-9794-366X

LinkedIn: www.linkedin.com/in/verena-battisti/

Showing entries 1 - 8 out of 8
Lombardo L, Battisti V, Langer T, Gitto R, De Luca L. Prediction of Activity and Selectivity Profiles of Sigma Receptor Ligands Using Machine Learning Approaches. Journal of Chemical Information and Modeling. 2025 Sept 22;65(18):9697-9712. Epub 2025 Sept 1. doi: 10.1021/acs.jcim.5c01091

Tillmanns J, Battisti V, Kicuntod J, Hahn F, Obergfäll D, Geiger P et al. The conserved core nuclear egress complex (NEC) as an antiherpesviral drug target: Pharmacophore-based identification of NEC-specific inhibitors. Antiviral Research. 2025 Jul;239:106168. doi: 10.1016/j.antiviral.2025.106168

Battisti V, Moesslacher J, Abdelnabi R, Leyssen P, Rosales Rosas AL, Langendries L et al. Design, synthesis, and lead optimization of piperazinyl-pyrimidine analogues as potent small molecules targeting the viral capping machinery of Chikungunya virus. European Journal of Medicinal Chemistry. 2024 Jan 15;264:116010. Epub 2023. doi: 10.1016/j.ejmech.2023.116010

Battisti V, Urban E, Langer T. Antivirals against the Chikungunya Virus. Viruses. 2021 Jul 5;13(7):1307. doi: 10.3390/v13071307

Abdelnabi R, Kovacikova K, Moesslacher J, Donckers K, Battisti V, Leyssen P et al. Novel Class of Chikungunya Virus Small Molecule Inhibitors That Targets the Viral Capping Machinery. Antimicrobial Agents and Chemotherapy. 2020 Jul;64(7):e00649-20. doi: 10.1128/AAC.00649-20

Moesslacher J, Battisti V, Delang L, Neyts J, Abdelnabi R, Pürstinger G et al. Identification of 2-(4-(Phenylsulfonyl) piperazine-1-yl) pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus. ACS Medicinal Chemistry Letters . 2020 May 14;11(5):906-912. doi: 10.1021/acsmedchemlett.9b00662

Ibric A, Battisti V, Deckardt S, Haller AV, Lee C, Prötsch C et al. A-ring and E-ring modifications of the cytotoxic alkaloid Luotonin A: Synthesis, computational and biological studies. Bioorganic & Medicinal Chemistry. 2020 May 1;28(9):115443. doi: 10.1016/j.bmc.2020.115443

Showing entries 1 - 8 out of 8